Download This PaperPharmaceutical Antitrust: What the Biden Administration Can Do
Concurrences, N° 1-2021
4 Pages Posted: 27 Jan 2021
Date Written: January 12, 2021
Abstract
To reduce high drug prices, this essay discusses four types of conduct the Biden administration can address: “pay for delay” settlements, “product hopping,” biosimilar blockades, and an ever-expanding frontier of new anticompetitive behavior.
Keywords: Antitrust, pharmaceuticals, drugs, pay-for-delay settlements, product hopping, biosimilars
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38
Suggested Citation: Suggested Citation
Carrier, Michael A., Pharmaceutical Antitrust: What the Biden Administration Can Do (January 12, 2021). Concurrences, N° 1-2021, Rutgers Law School Research Paper No. Forthcoming, Available at SSRN: https://ssrn.com/abstract=3771055
Michael A. Carrier (Contact Author)
Rutgers Law School ( email )
217 North Fifth Street
Camden, NJ 08102-1203
United States
856-225-6380 (Phone)
856-225-6516 (Fax)
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.